| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | MAB7442-SP | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB200-106SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB200-111SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-356SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-19775SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier-Free | NBP2-34952-500ug | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NB100-1921SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-87102-25ul | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-27406SS | |||
| Azide and BSA Free | NBP2-80834 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-52979SS | |||
![Western Blot: IL-1 beta/IL-1F2 Antibody [NB600-633] - Methylene blue (M) inhibits NLRP3 inflammasome formation in post-spinal cord injury (SCI) microglia compared to sham (V). Expression of pro-IL-1B and mature IL-1B in microglia sorted from post-SCI spinal cords. Representative Western blot images are shown in (B). Image collected and cropped by CiteAb from the following publication (//journal.frontiersin.org/article/10.3389/fncel.2017.00391/full) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/IL-1-beta-IL-1F2-Antibody-Western-Blot-NB600-633-img0012.jpg "<b>Biological Strategies Validation. </b>Western Blot: IL-1 beta/IL-1F2 Antibody [NB600-633] - Methylene blue (M) inhibits NLRP3 inflammasome formation in post-spinal cord injury (SCI) microglia compared to sham (V). Expression of pro-IL-1B and mature IL-1B in microglia sorted from post-SCI spinal cords. Representative Western blot images are shown in (B). Image collected and cropped by CiteAb from the following publication (//journal.frontiersin.org/article/10.3389/fncel.2017.00391/full) licensed under a CC-BY license.")
![<b>Biological Strategies Validation. </b>Immunocytochemistry/Immunofluorescence: IL-1 beta/IL-1F2 Antibody [NB600-633] - Trabecular Meshwork (TM) region of pig eyes were stained with IL-1 beta antibody (red). Image from verified customer review.](http://images.novusbio.com/fullsize/IL-1-beta-IL-1F2-Antibody-Immunocytochemistry-Immunofluorescence-NB600-633-img0009.jpg)
![Immunohistochemistry: IL-1 beta/IL-1F2 Antibody [NB600-633] - Analysis of: Human IL1beta antibody Secondary antibody: Peroxidase goat anti-rabbit at 1:10,000 for 45 min at RT Localization: cytoplasm Staining: Close up of medullary lymph node: positive staining in the cytoplasm of circulating macrophages. Neg Ctr (far right) normal rabbit IgG with pH 6.2 40X](http://images.novusbio.com/fullsize/IL-1-beta-IL-1F2-Antibody-Immunohistochemistry-NB600-633-img0010.jpg)
![Western Blot: IL-1 beta/IL-1F2 Antibody [NB600-633] - Analysis of IL-1 beta in Rhesus fetal membrane using anti-IL-1 beta antibody. Image from verified customer review.](http://images.novusbio.com/fullsize/IL-1-beta-IL-1F2-Antibody-Western-Blot-NB600-633-img0005.jpg)
![Western Blot: IL-1 beta/IL-1F2 Antibody [NB600-633] - Antibody was used at a 1:200 dilution incubated 1h at room temperature to detect dog IL-1b by Western blot. Lane 1 and 2 were loaded with 2.5 ug and 500 ng of dog IL-1b respectively. The molecular weight of the detected band is estimated by comparison to molecular weight markers (not shown). Detection occurred using a 1:3,000 dilution of IRDye (TM) 800 conjugated Donkey anti-Rabbit IgG for 1h at room temperature.](http://images.novusbio.com/fullsize/IL-1-beta-IL-1F2-Antibody-Western-Blot-NB600-633-img0006.jpg)
![Western Blot: IL-1 beta/IL-1F2 Antibody [NB600-633] - pro-IL-1beta in glioblastoma cells. Image from verified customer review.](http://images.novusbio.com/fullsize/IL-1-beta-IL-1F2-Antibody-Western-Blot-NB600-633-img0008.jpg)
![Western Blot: IL-1 beta/IL-1F2 Antibody [NB600-633] - Lane 1: Human IL-1Beta. Load: 5 ng per lane. Primary antibody: Human IL-1Beta antibody at 1:2,000 for overnight at 4C. Secondary antibody: Peroxidase rabbit secondary antibody at 1:40,000 for 30 min at RT. Block: Blocking Buffer for Fluorescent Western Blotting for 30 min at RT. Predicted/Observed size: 17 kDa, 17 kDa for Human IL-1Beta. Other band(s): Unspecific band at 35 kDa.](http://images.novusbio.com/fullsize/IL-1-beta-IL-1F2-Antibody-Western-Blot-NB600-633-img0011.jpg)
![Western Blot: IL-1 beta/IL-1F2 Antibody [NB600-633] - Methylene blue inhibits inflammasome formation in cultured microglia. (A) Expression of Pro-Caspase-1, Caspase-1 p20, pro-IL-1 beta & mature IL-1 beta in microglia with or without stimulation in the presence or absence of methylene blue. Left: representative Western blot images. Right: statistics. N = 5 per group. The (B) expression of NLRP3, NLRC4 & Aim2 in microglia. Left: representative Western blot images. Right: statistics. N = 4 per group. (C) Co-immunoprecipitation assay showing the binding of ASC to NLRP3 or NLRC4. Left: representative Western blot images. Right: statistics. Un: no stimulation. LPS+ATP: stimulation with LPS followed by ATP treatment. V: vehicle; M: 500 nM methylene blue. IP: immunoprecipitation with the antibody against indicated protein. IB: detection of indicated protein. To analyze the relative expression of target proteins, the band intensities of target proteins were normalized to corresponding band intensities of alpha -Tubulin, followed by calculating the expression in other groups relative to “Un (V)” group. N = 4 per group. *p < 0.05; **p < 0.01; ***p < 0.001 in comparison with unstimulated cells of the vehicle group. #p < 0.05; ##p < 0.01 in comparison with stimulated cells of the vehicle group. Image collected & cropped by CiteAb from the following publication (//journal.frontiersin.org/article/10.3389/fncel.2017.00391/full), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb600-633_rabbit-polyclonal-il-1-beta-il-1f2-antibody-310202416165633.jpg)
![Western Blot: Rabbit Polyclonal IL-1 beta/IL-1F2 Antibody [NB600-633] - IL-1 beta/IL-1F2 Western blot of liver homogenate from control (1) and alcohol-fed mice (2). Image from a verified customer review.](http://images.novusbio.com/fullsize/antibody/nb600-633_rabbit-polyclonal-il-1-beta-il-1f2-antibody-western-blot-25112024153834..png)
![Western Blot: TL1A/TNFSF15 Antibody (2116C) [MAB7442] - Analysis of human prostate, kidney, and lung tissue lysates with 1 ug/ml of hTL1A Monoclonal Antibody followed by HRP-conjugated Anti-Rabbit IgG Antibody. A specific band was detected for hTL1A at approximately 22 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1.](http://images.novusbio.com/fullsize/TL1A-TNFSF15-Antibody-2116C-Western-Blot-MAB7442-img0001.jpg "Western Blot: TL1A/TNFSF15 Antibody (2116C) [MAB7442] - Analysis of human prostate, kidney, and lung tissue lysates with 1 ug/ml of hTL1A Monoclonal Antibody followed by HRP-conjugated Anti-Rabbit IgG Antibody. A specific band was detected for hTL1A at approximately 22 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1.")
![Western Blot: p19ARF/CDKN2A Antibody [NB200-106] - Analysis of p19ARF/CDKN2A in (A) NIH/3T3 and (B) MEF cells.](http://images.novusbio.com/fullsize/p19ARF-CDKN2A-Antibody-Western-Blot-NB200-106-img0010.jpg "Western Blot: p19ARF/CDKN2A Antibody [NB200-106] - Analysis of p19ARF/CDKN2A in (A) NIH/3T3 and (B) MEF cells.")
![Immunocytochemistry/Immunofluorescence: p19ARF/CDKN2A Antibody [NB200-106] - Antibody was tested in MEF cells with DyLight 488 (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and DyLight 550 (red).](http://images.novusbio.com/fullsize/p19ARF-Antibody-Immunocytochemistry-Immunofluorescence-NB200-106-img0004.jpg)
![Immunohistochemistry: p19ARF/CDKN2A Antibody [NB200-106] - Adult mouse kidney (glomerulus). Image from verified customer review.](http://images.novusbio.com/fullsize/p19ARF-Antibody-Immunocytochemistry-Immunofluorescence-NB200-106-img0006.jpg)
![Immunohistochemistry-Paraffin: p19ARF/CDKN2A Antibody [NB200-106] - Analysis of FFPE mouse spleen using p19ARF/CDKN2A antibody at 10 ug/mL on a Bond Rx autostainer (Leica Biosystems). The assay involved 20 minutes of heat induced antigen retrieval (HIER) using 10mM sodium citrate buffer (pH 6.0) and endogenous peroxidase quenching with peroxide block. The sections were incubated with primary antibody for 30 minutes and Bond Polymer Refine Detection (Leica Biosystems) with DAB was used for signal development followed by counterstaining with hematoxylin. Whole slide scanning and capturing of representative images was performed using Aperio AT2 (Leica Biosystems). Nuclear staining in the germinal centers of spleen was observed. Staining was performed by Histowiz.](http://images.novusbio.com/fullsize/p19ARF-Antibody-Immunohistochemistry-Paraffin-NB200-106-img0005.jpg)
![Western Blot: p14ARF/CDKN2A Antibody [NB200-111] - Inhibition of AKT decreases p53mut stability. T24 cells were transfected with non-targeting control, AKT1, or p14ARF siRNA. Cells were treated with NCS348884 (4 i1/4M), Nutlin3A (5 i1/4M) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. Image collected and cropped by Citeab from the following publication (AKT regulates NPM dependent ARF localization and p53mut stability in tumors. Oncotarget (2014)) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Western-Blot-NB200-111-img0012.jpg "<b>Genetic Strategies Validation. </b>Western Blot: p14ARF/CDKN2A Antibody [NB200-111] - Inhibition of AKT decreases p53mut stability. T24 cells were transfected with non-targeting control, AKT1, or p14ARF siRNA. Cells were treated with NCS348884 (4 i1/4M), Nutlin3A (5 i1/4M) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. Image collected and cropped by Citeab from the following publication (AKT regulates NPM dependent ARF localization and p53mut stability in tumors. Oncotarget (2014)) licensed under a CC-BY license.")
![<b>Genetic Strategies Validation. </b>Immunohistochemistry: p14ARF/CDKN2A Antibody [NB200-111] - Inhibition of AKT modulates p53 stability in-vivo and synergizes with ionizing radiation to inhibit tumor growth( Sections of PSN1 xenografts treated with three consecutive doses of MK-2206 (60 mg/kg). Sections of PSN1 xenografts and in-vitro PSN1 cells fixed and stained with anti-NPM (red) and anti-p14ARF (green). Image collected and cropped by Citeab from the following publication (AKT regulates NPM dependent ARF localization and p53mut stability in tumors. Oncotarget (2014)) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Immunocytochemistry-Immunofluorescence-NB200-111-img0011.jpg)
![Immunocytochemistry/Immunofluorescence: p14ARF/CDKN2A Antibody [NB200-111] - p14ARF antibody was tested in HeLa cells with Dylight 488 (green). Nuclei were counterstained with DAPI (blue). Tubulin was stained with alpha tubulin (red).](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Immunocytochemistry-Immunofluorescence-NB200-111-img0006.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: p14ARF/CDKN2A Antibody [NB200-111] - ARF expression levels in OCI/AML3 cells after proteasome treatment. This image was submitted via customer Review.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Western-Blot-NB200-111-img0009.jpg)
![Flow Cytometry: p14ARF/CDKN2A Antibody [NB200-111] - p14ARF antibody was tested at 1:400 in HeLa cells using an Alexa Fluor 488 secondary (shown in purple). M1 is defined by unstained cells.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Flow-Cytometry-NB200-111-img0007.jpg)
![Western Blot: p14ARF/CDKN2A Antibody [NB200-111] - Analysis of HeLa Whole Cell Lysate (NB800-PC1) using p14ARF antibody (lot C) employing ECL detection method.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Western-Blot-NB200-111-img0008.jpg)
![Immunohistochemistry-Frozen: p14ARF/CDKN2A Antibody [NB200-111] - Mouse brain section, hippocampal (10 um thickness). 3% PFA perfused. 1:1000 dilultion. Image from verified customer review. Image using the Biotin form of this antibody.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Immunohistochemistry-Frozen-NB200-111-img0010.jpg)
![Western Blot: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT decreases p53mut stability(A) T24 cells & PSN1 cells were treated with MK-2206 (5 μM) or DMSO for 24 hrs. Cells were fixed & stained with DAPI & anti-mutant p53 (OP29 clone). (B) T24 cells were pre-treated with MK-2206 (5 μM) or DMSO for 24 hrs before the addition of fresh media containing cyclohexamide (100 μM) (CHX) in combination with MK-2206 (5 μM) or DMSO for the times indicated. Nuclear extracts were prepared from treated cells & blotted with the indicated antibodies. Quantification is relative to initiation of CHX treatment for both conditions *, MK-2206 is 40% of DMSO control but taken as 1.0 for relative assessment. (C) H1299 cells were transfected with HA-tagged-ubiquitin & mutant p53 (R175H or R248W) as indicated. Transfected cells were treated with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) for 16hrs as indicated. p53 immunoprecipitates & whole cell lysates were probed with the indicated antibodies. (D) T24 cells were transfected with non-targeting control or p14ARF siRNA & treated with DMSO, MK-2206 (5 μM) or the NPM oligomerisation inhibitor NCS348884 (4 μM) (Qi et al., 2008) as indicated. (E) T24 cells were transfected with non-targeting control, AKT1, or p14ARF siRNA. Cells were treated with NCS348884 (4 μM), Nutlin3A (5 μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. (F) KPC mice derived KRASG12D p53 Floxed (p53Fl), KRASG12D p53R172H ARF+/+ & KRASG12D p53R172H ARF−/− pancreatic tumor cells were treated with MK-2206 (1μM), Nutlin3A (5μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416203719.jpg)
![Western Blot: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT decreases p53mut stability(A) T24 cells & PSN1 cells were treated with MK-2206 (5 μM) or DMSO for 24 hrs. Cells were fixed & stained with DAPI & anti-mutant p53 (OP29 clone). (B) T24 cells were pre-treated with MK-2206 (5 μM) or DMSO for 24 hrs before the addition of fresh media containing cyclohexamide (100 μM) (CHX) in combination with MK-2206 (5 μM) or DMSO for the times indicated. Nuclear extracts were prepared from treated cells & blotted with the indicated antibodies. Quantification is relative to initiation of CHX treatment for both conditions *, MK-2206 is 40% of DMSO control but taken as 1.0 for relative assessment. (C) H1299 cells were transfected with HA-tagged-ubiquitin & mutant p53 (R175H or R248W) as indicated. Transfected cells were treated with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) for 16hrs as indicated. p53 immunoprecipitates & whole cell lysates were probed with the indicated antibodies. (D) T24 cells were transfected with non-targeting control or p14ARF siRNA & treated with DMSO, MK-2206 (5 μM) or the NPM oligomerisation inhibitor NCS348884 (4 μM) (Qi et al., 2008) as indicated. (E) T24 cells were transfected with non-targeting control, AKT1, or p14ARF siRNA. Cells were treated with NCS348884 (4 μM), Nutlin3A (5 μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. (F) KPC mice derived KRASG12D p53 Floxed (p53Fl), KRASG12D p53R172H ARF+/+ & KRASG12D p53R172H ARF−/− pancreatic tumor cells were treated with MK-2206 (1μM), Nutlin3A (5μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416212372.jpg)
![Immunocytochemistry/ Immunofluorescence: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT modulates p53 stability in-vivo & synergizes with ionizing radiation to inhibit tumor growth(A) PSN1 xenografts (PSN1 cells co-injected with LTC-14 stellate cells) established in the flank of athymic nude mice were treated with MK-2206 (60 mg/kg-320 mg/kg) as indicated or beta -cyclo-dextrin (1.5 mg/ml) carrier. Xenograft tumors were lysed & lysates probed by western blot with the indicated antibodies. (B-D) Sections of PSN1 xenografts treated with three consecutive doses of MK-2206 (60 mg/kg). (B) Sections of PSN1 xenografts & in-vitro PSN1 cells fixed & stained with anti-NPM (red) & anti-p14ARF (green). (C) PSN1 xenografts treated with MK-2206 or carrier were stained with DAPI, anti-p53 (DO1) or p53mut (OP29 clone) (D) PSN1 xenografts treated with MK-2206 (60 mg/kg) or carrier were stained by immunohistochemical methods with anti-pS473-AKT, anti-phospho-S48-NPM (pS48-NPM) or p53. (E) PSN1 xenografts established in the flank of athymic nude mice were injected subcutaneously with two alternate day doses of MK-2206 (60 mg/kg) or carrier. Mice were subsequently treated with a single dose of IR (6 Gy) & tumor volumes measured regularly with callipers. Dash lines indicate tumor growth differential at 250 mm3. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416203724.jpg)
![Western Blot: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT decreases p53mut stability(A) T24 cells & PSN1 cells were treated with MK-2206 (5 μM) or DMSO for 24 hrs. Cells were fixed & stained with DAPI & anti-mutant p53 (OP29 clone). (B) T24 cells were pre-treated with MK-2206 (5 μM) or DMSO for 24 hrs before the addition of fresh media containing cyclohexamide (100 μM) (CHX) in combination with MK-2206 (5 μM) or DMSO for the times indicated. Nuclear extracts were prepared from treated cells & blotted with the indicated antibodies. Quantification is relative to initiation of CHX treatment for both conditions *, MK-2206 is 40% of DMSO control but taken as 1.0 for relative assessment. (C) H1299 cells were transfected with HA-tagged-ubiquitin & mutant p53 (R175H or R248W) as indicated. Transfected cells were treated with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) for 16hrs as indicated. p53 immunoprecipitates & whole cell lysates were probed with the indicated antibodies. (D) T24 cells were transfected with non-targeting control or p14ARF siRNA & treated with DMSO, MK-2206 (5 μM) or the NPM oligomerisation inhibitor NCS348884 (4 μM) (Qi et al., 2008) as indicated. (E) T24 cells were transfected with non-targeting control, AKT1, or p14ARF siRNA. Cells were treated with NCS348884 (4 μM), Nutlin3A (5 μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. (F) KPC mice derived KRASG12D p53 Floxed (p53Fl), KRASG12D p53R172H ARF+/+ & KRASG12D p53R172H ARF−/− pancreatic tumor cells were treated with MK-2206 (1μM), Nutlin3A (5μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416205197.jpg)
![Western Blot: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT promotes enhanced MDM2 activity via the increased association between NPM & p14ARF(A) Npm−/−, p53−/−double null MEF were infected with pBABE retrovirus empty vector & pBABE expressing FLAG-tagged-NPM-WT, NPM-S48A or S48E as indicated. Immunopurification of NPM was done by pulling down with the Flag tag (middle panel) followed by elution of complexes by the Flag peptide & subsequent immunopurification of endogenous MDM2 (lower panel). (B) Nuclear immunoprecipitates of MDM2 from T24 cells treated with MK-2206 (5 μM, 24 hrs). Immunoprecipitates & lysates were blotted with the indicated antibodies. (C) T24 cells were treated with MK-2206 (5 μM) as indicated. p14ARF was immunoprecipitated from whole cell lysates & nuclear extracts & the association with NPM & MDM2 determined by western blot. Immunoprecipitates & lysates were blotted with the indicated antibodies. (D) MDM2 & (E) p53 ubiquinitation assay in H1299 cells transfected with wild type p53, HA-tagged ubiquitin & treated for 16 hrs with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) as indicated. Immunoprecipitates & whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416212370.jpg)
![Western Blot: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT promotes enhanced MDM2 activity via the increased association between NPM & p14ARF(A) Npm−/−, p53−/−double null MEF were infected with pBABE retrovirus empty vector & pBABE expressing FLAG-tagged-NPM-WT, NPM-S48A or S48E as indicated. Immunopurification of NPM was done by pulling down with the Flag tag (middle panel) followed by elution of complexes by the Flag peptide & subsequent immunopurification of endogenous MDM2 (lower panel). (B) Nuclear immunoprecipitates of MDM2 from T24 cells treated with MK-2206 (5 μM, 24 hrs). Immunoprecipitates & lysates were blotted with the indicated antibodies. (C) T24 cells were treated with MK-2206 (5 μM) as indicated. p14ARF was immunoprecipitated from whole cell lysates & nuclear extracts & the association with NPM & MDM2 determined by western blot. Immunoprecipitates & lysates were blotted with the indicated antibodies. (D) MDM2 & (E) p53 ubiquinitation assay in H1299 cells transfected with wild type p53, HA-tagged ubiquitin & treated for 16 hrs with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) as indicated. Immunoprecipitates & whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416205120.jpg)
![Immunohistochemistry: Cyr61/CCN1 Antibody [NB100-356] - Sections of the ectopic lesions collected from E2 or E2 plus P4-treated recipients (D16, n = 6) were subjected to histological examination. (B) Representative images (20X) showing IHC analysis using antibodies against an angiogenetic regulator CCN1. The immunostaining intensity of CCN1 was analyzed by ImageJ software. The numerical values were analyzed by One-way ANOVA followed by Dunnett's post hoc test and expressed as mean +/- SEM. Statistical significance is defined as *: p<0.01. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0165347) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Cyr61-CCN1-Antibody-Immunohistochemistry-NB100-356-img0007.jpg "Immunohistochemistry: Cyr61/CCN1 Antibody [NB100-356] - Sections of the ectopic lesions collected from E2 or E2 plus P4-treated recipients (D16, n = 6) were subjected to histological examination. (B) Representative images (20X) showing IHC analysis using antibodies against an angiogenetic regulator CCN1. The immunostaining intensity of CCN1 was analyzed by ImageJ software. The numerical values were analyzed by One-way ANOVA followed by Dunnett's post hoc test and expressed as mean +/- SEM. Statistical significance is defined as *: p<0.01. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0165347) licensed under a CC-BY license.")
![<b>Biological Strategies Validation. </b>Western Blot: Cyr61/CCN1 Antibody [NB100-356] - Total protein from Human liver, spleen and HepG2 cells was separated on a 12% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 2.0 ug/mL anti-CYR61 in 1% non-fat milk in TBST and detected with an anti-rabbit HRP secondary antibody using chemiluminescence. Note the low expression level of CYR61 in HepG2 cells.](http://images.novusbio.com/fullsize/Cyr61-CCN1-Antibody-Western-Blot-NB100-356-img0006.jpg)
![Immunocytochemistry/Immunofluorescence: Cyr61/CCN1 Antibody [NB100-356] - MCF7 cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X TBS + 0.5% Triton X-100. The cells were incubated with anti-Cyr61/CCN1 (NB100-356) at 1:200 overnight at 4C and detected with an anti-rabbit DyLight 488 (Green) at 1:500. Alpha tubulin was used as a co-stain at 1:1000 and detected with an anti-mouse DyLight 550 (Red) at a 1:500 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/Cyr61-CCN1-Antibody-Immunocytochemistry-Immunofluorescence-NB100-356-img0005.jpg)
![Western Blot: Cyr61/CCN1 Antibody [NB100-356] - Detection of cleaved CYR61 in MDA-MB-231 cell lysate using NB 100-356. Photo courtesy of Dr. Lupu's Lab, Northwestern University. Image by Dr. Ingrid Espinoza.](http://images.novusbio.com/fullsize/Cyr61-CCN1-Antibody-Western-Blot-NB100-356-img0004.jpg)
![Immunohistochemistry: Cyr61/CCN1 Antibody [NB100-356] - Human endometrium. Photo courtesy of Dr. rer. nat. Isabella Gashaw, University Duisburg-Essen.](http://images.novusbio.com/fullsize/Cyr61-CCN1-Antibody-Immunohistochemistry-NB100-356-img0001.jpg)
![Immunohistochemistry: Cyr61/CCN1 Antibody [NB100-356] - Human endometrium. Photo courtesy of Dr. rer. nat. Isabella Gashaw, University Duisburg-Essen.](http://images.novusbio.com/fullsize/Cyr61-CCN1-Antibody-Immunohistochemistry-NB100-356-img0002.jpg)
![Simple Western: Cyr61/CCN1 Antibody [NB100-356] - Image shows a specific band for CYR61 in 0.5 mg/mL of MCF-7 lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/Cyr61-CCN1-Antibody-Simple-Western-NB100-356-img0003.jpg)
![Immunocytochemistry/ Immunofluorescence: Cyr61/CCN1 Antibody - BSA Free [NB100-356] - P4 inhibits E2-dependent cell proliferation & angiogenesis in ectopic lesions.Sections of the ectopic lesions collected from E2 or E2 plus P4-treated recipients (D16, n = 6) were subjected to histological examination. (A) Representative images (20X) showing H&E & Trichrome staining, or IHC analysis using antibody against myofibroblast biomarker alpha SMA, uterine epithelial biomarker KRT11, or uterine stromal biomarker VIM, respectively. (B) Representative images (20X) showing IHC analysis using antibodies against cell proliferation biomarker KI67, smooth muscle biomarker alpha SMA, endothelial cells CD31, or an angiogenetic regulator CCN1, respectively. The numbers of KI67-positive cells, the perimeters of the supporting blood vessels, & the immunostaining intensities of CCN1 & CD31 were analyzed by ImageJ software. The numerical values were analyzed by One-way ANOVA followed by Dunnett’s post hoc test & expressed as mean ± SEM. Statistical significance is defined as #: p < 0.05, *: p<0.01. Image collected & cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0165347), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-356_rabbit-polyclonal-cyr61-ccn1-antibody-310202415525265.jpg)
![Western Blot: IL-1 beta/IL-1F2 Antibody [NBP1-19775] - Analysis of IL1 beta Antibody in extracts from HeLa cells.](http://images.novusbio.com/fullsize/IL-1-beta-IL-1F2-Antibody-Western-Blot-NBP1-19775-img0004.jpg "Western Blot: IL-1 beta/IL-1F2 Antibody [NBP1-19775] - Analysis of IL1 beta Antibody in extracts from HeLa cells.")
![Immunohistochemistry: IL-1 beta/IL-1F2 Antibody - BSA Free [NBP1-19775] - In situ expression of IL-6 in glomerular and tubulointerstitial compartments in patients with diabetic nephropathy DN (right) and control group (left). Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32723296/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/IL-1-beta-IL-1F2-Antibody---BSA-Free-Immunohistochemistry-NBP1-19775-img0006.jpg)
![Immunohistochemistry: IL-1 beta/IL-1F2 Antibody [NBP1-19775] - Staining in the cytoplasm of villi and in the crypt cells of human lung carcinoma tissue.](http://images.novusbio.com/fullsize/IL-1-beta-IL-1F2-Antibody-Immunohistochemistry-NBP1-19775-img0005.jpg)
![Western Blot: IL-1 beta/IL-1F2 Antibody [NBP1-42767] - Analysis using the HRP conjugate of NBP1-42767. Detection of Lane 1: Mouse IL-1 Beta Load: 50 ug per Detection of Lane Secondary antibody: IL1 beta Antibody Peroxidase conjugated at 1:1,000 for 30 min at RT Block for30 min RT Predicted/Observed size: 18 kDa, 18 kDa.](http://images.novusbio.com/fullsize/IL-1-beta-IL-1F2-Antibody-Western-Blot-NBP1-42767-img0012.jpg "Western Blot: IL-1 beta/IL-1F2 Antibody [NBP1-42767] - Analysis using the HRP conjugate of NBP1-42767. Detection of Lane 1: Mouse IL-1 Beta Load: 50 ug per Detection of Lane Secondary antibody: IL1 beta Antibody Peroxidase conjugated at 1:1,000 for 30 min at RT Block for30 min RT Predicted/Observed size: 18 kDa, 18 kDa.")
![Immunocytochemistry/Immunofluorescence: IL-1 beta/IL-1F2 Antibody [NBP1-42767] - Staining of mouse carotid artery. A) No Ab staining of WT uninjured Ms. B) IL-1 beta staining of cells after surgical injury of tissue. C) No Ab staining of injured tissue from an IL-1 beta KO.](http://images.novusbio.com/fullsize/IL-1-beta-IL-1F2-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-42767-img0004.jpg)
![Immunohistochemistry: IL-1 beta/IL-1F2 Antibody [NBP1-42767] - Analysis of Mouse Embryonic Kidney Tissue: Mouse Embryonic Kidney Fixation: FFPE buffered formalin 10% conc Ag Retrieval: Heat, Citrate pH 6.2. Pressure Cooker Primary antibody: 2ug/ml 1.5 hour @ room T Secondary Ab: MACH 1 HRP POLYMER 1:50 45C RT](http://images.novusbio.com/fullsize/IL-1-beta-IL-1F2-Antibody-Immunohistochemistry-NBP1-42767-img0010.jpg)
![Western Blot: IL-1 beta/IL-1F2 Antibody [NBP1-42767] - Analysis using the Biotin conjugate of NBP1-42767. Detection of Lane 1: Mouse IL-1beta Recombinant Protein. Load: 50 ng per lane. Used at a dilution of 1:1,000 overnight at 4C.](http://images.novusbio.com/fullsize/IL-1-beta-IL-1F2-Antibody-Western-Blot-NBP1-42767-img0008.jpg)
![Western Blot: IL-1 beta/IL-1F2 Antibody [NBP1-42767] - Detects 10% of the non-denatured (native) precursor 31,000 MW mouse IL-1Beta containing samples but will primarily detect all of the 17,000 MW mature molecule. However, in western blot analysis, the usual procedure of heating the sample in SDS with or without reducing agents will facilitate denaturing of the 31,000 MW IL- 1Beta precursor molecule. Denatured IL-1Beta will have a 18 kDa band.](http://images.novusbio.com/fullsize/IL-1-beta-IL-1F2-Antibody-Western-Blot-NBP1-42767-img0011.jpg)
![SDS-Page: Human EGF Protein [NBP2-34952]](http://images.novusbio.com/fullsize/Human-EGF-Protein-SDS-Page-NBP2-34952-img0003.jpg "SDS-Page: Human EGF Protein [NBP2-34952]")
![Immunohistochemistry-Paraffin: S100B Antibody [NBP1-87102] - Analysis in human cerebral cortex and liver tissues. Corresponding S100B RNA-seq data are presented for the same tissues.](http://images.novusbio.com/fullsize/S100B-Antibody-Immunohistochemistry-Paraffin-NBP1-87102-img0020.jpg "<b>Orthogonal Strategies Validation. </b>Immunohistochemistry-Paraffin: S100B Antibody [NBP1-87102] - Analysis in human cerebral cortex and liver tissues. Corresponding S100B RNA-seq data are presented for the same tissues.")
![<b>Orthogonal Strategies Validation. </b>Western Blot: S100B Antibody [NBP1-87102] - Analysis in mouse cerebral cortex tissue.](http://images.novusbio.com/fullsize/S100B-Antibody-Western-Blot-NBP1-87102-img0010.jpg)
![Immunocytochemistry/Immunofluorescence: S100B Antibody [NBP1-87102] - Staining of human cell line U-2 OS shows localization to vesicles. Antibody staining Is shown in green.](http://images.novusbio.com/fullsize/S100B-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-87102-img0018.jpg)
![Immunohistochemistry-Paraffin: S100B Antibody [NBP1-87102] - Staining of human skeletal muscle shows no positivity in myocytes as expected.](http://images.novusbio.com/fullsize/S100B-Antibody-Immunohistochemistry-Paraffin-NBP1-87102-img0025.jpg)
![Immunohistochemistry-Paraffin: S100B Antibody [NBP1-87102] - Staining of human cerebellum shows moderate to strong nuclear positivity in cells in purkinje cell layer.](http://images.novusbio.com/fullsize/S100B-Antibody-Immunohistochemistry-Paraffin-NBP1-87102-img0022.jpg)
![Immunohistochemistry-Paraffin: S100B Antibody [NBP1-87102] - Staining of human cerebral cortex shows moderate to strong nuclear positivity in glial cells.](http://images.novusbio.com/fullsize/S100B-Antibody-Immunohistochemistry-Paraffin-NBP1-87102-img0023.jpg)
![Immunohistochemistry-Paraffin: S100B Antibody [NBP1-87102] - Staining of human liver shows no positivity in hepatocytes as expected.](http://images.novusbio.com/fullsize/S100B-Antibody-Immunohistochemistry-Paraffin-NBP1-87102-img0024.jpg)
![Western Blot: LIF Antibody (39N7D10) [NBP2-27406] - LIF expression in human primary T-cells and cancer cell lines: Jurkat and K562. Image from verified customer review.](http://images.novusbio.com/fullsize/LIF-Antibody-39N7D10-Western-Blot-NBP2-27406-img0009.jpg "Western Blot: LIF Antibody (39N7D10) [NBP2-27406] - LIF expression in human primary T-cells and cancer cell lines: Jurkat and K562. Image from verified customer review.")
![Immunohistochemistry-Paraffin: LIF Antibody (39N7D10) [NBP2-27406] - Tissue section of mouse brain using 5 ug/ml concentration of LIF antibody (clone 39N7D10).](http://images.novusbio.com/fullsize/LIF-Antibody-39N7D10-Immunohistochemistry-Paraffin-NBP2-27406-img0008.jpg)
![Western Blot: LIF Antibody (39N7D10) [NBP2-27406] - WB validation of LIF antibody (clone 39N7D10) on (A) full-length recombinant Lif protein, (B) mouse spleen lysate and (C) human spleen lysate. 3 ug/mL concentration of primary antibody, Goat anti-rat IgG HRP secondary antibody and PicoTect ECL substrate solution were used for this assay.](http://images.novusbio.com/fullsize/LIF-Antibody-39N7D10-Western-Blot-NBP2-27406-img0001.jpg)
![Immunohistochemistry-Paraffin: LIF Antibody (39N7D10) [NBP2-27406] - Tissue section of normal human prostate using 5 ug/ml concentration of LIF antibody (clone 39N7D10). Cell surface/membrane- cytoplasmic immunepositivity of LIF was observed specifically in the epithelial cells of prostate alveolar glands, whereas the surrounding fibromuscular stroma cells did not develop any staining.](http://images.novusbio.com/fullsize/LIF-Antibody-39N7D10-Immunohistochemistry-Paraffin-NBP2-27406-img0002.jpg)
![Immunohistochemistry-Paraffin: LIF Antibody (39N7D10) [NBP2-27406] - Tissue section of normal human kidney using 5 ug/ml concentration of LIF antibody (clone 39N7D10). Expected membrane- cytoplasmic immunepositivity of LIF was observed in the cuboidal epithelial cells of renal tubules.](http://images.novusbio.com/fullsize/LIF-Antibody-39N7D10-Immunohistochemistry-Paraffin-NBP2-27406-img0003.jpg)
![Immunohistochemistry-Paraffin: LIF Antibody (39N7D10) [NBP2-27406] - Tissue section of adenocarcinoma of human rectum using 5 ug/ml concentration of LIF antibody (clone 39N7D10). The cancer cells as well as the goblet cells in the rectal glands depicted membrane-cytoplasmic immunostaining of LIF protein.](http://images.novusbio.com/fullsize/LIF-Antibody-39N7D10-Immunohistochemistry-Paraffin-NBP2-27406-img0004.jpg)
![Immunohistochemistry-Paraffin: LIF Antibody (39N7D10) [NBP2-27406] - Tissue section of mouse colon using 5 ug/ml concentration of LIF antibody (clone 39N7D10). The columnar epithelial cells of the crypts developed intense membrane-cytoplasmic LIF immunostaining. Additionally, some cells in the lamina propria and the sub-mucosal layer also depicted weak positivity for LIF staining.](http://images.novusbio.com/fullsize/LIF-Antibody-39N7D10-Immunohistochemistry-Paraffin-NBP2-27406-img0006.jpg)
![Immunohistochemistry-Paraffin: LIF Antibody (39N7D10) [NBP2-27406] - Tissue section of mouse kidney using 5 ug/ml concentration of LIF antibody (clone 39N7D10). Very intense immune positivity of LIF was observed in membranes as well as the cytoplasm of cuboidal epithelial cells of renal tubules.](http://images.novusbio.com/fullsize/LIF-Antibody-39N7D10-Immunohistochemistry-Paraffin-NBP2-27406-img0007.jpg)
![Immunocytochemistry/Immunofluorescence: Apolipoprotein A-I/ApoA1 Antibody - BSA Free [NBP2-52979] - HepG2 cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.05% Triton X-100 in PBS for 5 minutes. The cells were incubated with Apolipoprotein A-1/ApoA1 Antibody (NBP2-52979) at 1ug/ml overnight at 4C and detected with an anti-rabbit DyLight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/Apolipoprotein-A-I-ApoA1-Antibody---BSA-Free-Immunocytochemistry-Immunofluorescence-NBP2-52979-img0006.jpg "Immunocytochemistry/Immunofluorescence: Apolipoprotein A-I/ApoA1 Antibody - BSA Free [NBP2-52979] - HepG2 cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.05% Triton X-100 in PBS for 5 minutes. The cells were incubated with Apolipoprotein A-1/ApoA1 Antibody (NBP2-52979) at 1ug/ml overnight at 4C and detected with an anti-rabbit DyLight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.")
![Western Blot: Apolipoprotein A-I/ApoA1 Antibody [NBP2-52979] - Western blot analysis using Apolipoprotein A-I/ApoA1 antibody. Harvested from mouse, separated on a 4-12 gradient gel by SDS-PAGE, transferred to PVDF membrane and blocked in 3% BSA/TBST. Probed with 1:8000 anti-apoA1 in 1%BSA/TBST, and detect edwith an anti-rabbit HRP secondary antibody using chemiluminescence. WB dilution 1: 8000, block before incubation overnight. Image from verified customer review.](http://images.novusbio.com/fullsize/Apolipoprotein-A-I-ApoA1-Antibody-Western-Blot-NBP2-52979-img0005.jpg)
![Immunocytochemistry/Immunofluorescence: Apolipoprotein A-I/ApoA1 Antibody - BSA Free [NBP2-52979] - HepG2 cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.05% Triton X-100 in PBS for 5 minutes. The cells were incubated with Apolipoprotein A-1/ApoA1 Antibody conjugated to FITC (NBP2-52979F) at 5ug/ml for 1 hour at room temperature. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/Apolipoprotein-A-I-ApoA1-Antibody---BSA-Free-Immunocytochemistry-Immunofluorescence-NBP2-52979-img0007.jpg)
![Immunohistochemistry-Paraffin: Apolipoprotein A-I/ApoA1 Antibody [NBP2-52979] - IHC analysis of a formalin fixed and paraffin embedded tissue section of mouse liver using APOA1 antibody at 1:400 dilution. The antibody generated a weak/mild cytoplasmic signal in hepatocytes with a very strong positivity near the hepatocyte membranes as well as in the inter-cellular spaces.](http://images.novusbio.com/fullsize/Apolipoprotein-A-I-ApoA1-Antibody-Immunohistochemistry-Paraffin-NBP2-52979-img0002.jpg)
![Flow Cytometry: Apolipoprotein A-I/ApoA1 Antibody [NBP2-52979] - An intracellular stain was performed on HepG2 cells with Apolipoprotein A-1/ApoA1 Antibody NBP2-52979 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 1.0 ug/mL for 30 minutes at room temperature, followed by Rabbit IgG (H+L) Cross-Adsorbed Secondary Antibody, .](http://images.novusbio.com/fullsize/Apolipoprotein-A-I-ApoA1-Antibody-Flow-Cytometry-NBP2-52979-img0004.jpg)
![Western Blot: Apolipoprotein A-I/ApoA1 Antibody [NBP2-52979] - Total protein from HepG2 and Hek293 cells was separated on a 4-15% gradient gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 1.0 ug/ml anti-APOA1 in 1% milk, and detected with an anti-rabbit HRP secondary antibody using chemiluminescence.](http://images.novusbio.com/fullsize/Apolipoprotein-A-I-ApoA1-Antibody-Western-Blot-NBP2-52979-img0003.jpg)
![Immunocytochemistry/Immunofluorescence: Apolipoprotein A-I/ApoA1 Antibody [NBP2-52979] - HepG2 cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X TBS + 0.5% Triton-X100. The cells were incubated with anti-APOA1 at a 1:200 dilution overnight at 4C and detected with an anti-rabbit Dylight 488 (Green) at a 1:500 dilution. Alpha tubulin (DM1A) NB100-690 was used as a co-stain at a 1:1000 dilution and detected with an anti-mouse Dylight 550 (Red) at a 1:500 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/Apolipoprotein-A-I-ApoA1-Antibody-Immunocytochemistry-Immunofluorescence-NBP2-52979-img0001.jpg)
